Skip to Content

Albireo Pharma, Inc.

Merger

  • Date:
  • 1/9/2023
  • Company Name:
  • Albireo Pharma, Inc.
  • Stock Symbol:
  • ALBO
  • Company Name - Buyer:
  • Ipsen
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 1/9/2023

Case Finder

Locate any case using the tools below.

NEW YORK, January 9, 2023 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Albireo Pharma, Inc. (NASDAQ: ALBO) (“Albireo”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Ipsen.

On January 9, 2023, Albireo announced that it had entered into an agreement to be acquired by Ipsen in a cash and CVR deal. Pursuant to the merger agreement, Ipsen will acquire Albireo for $42.00 per share in cash plus one non-tradeable contractual contingent value right per Share representing the right to receive a contingent payment of $10.00 per Share, net to the holder in cash, without interest, upon the achievement of the milestone set forth in the CVR Agreement.

Bragar Eagel & Squire is concerned that Albireo’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Albireo’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Albireo Pharma. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: